Kaposi sarcoma - null regimens
Revision as of 12:55, 14 October 2023 by Warner-admin (talk | contribs) (Text replacement - "]] for current regimens." to "]] for regimens that include active anticancer treatment.")
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main KS page for regimens that include active anticancer treatment.
All lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Noy et al. 2005 (AMC 013) | 1998-2001 | Phase 3 (C) | IM-862 | Seems to have superior TTP |
No active antineoplastic treatment.
References
- AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed